Products
Biota's development program has produced a number of innovative products which have been commercialised and marketed by licensees or partners.
Those products include:
- Zanamivir; the first in-class neuraminidase inhibitor for the treatment and prophylaxis of influenza, initially launched in 1999 and marketed as Relenza™ by GlaxoSmithKline.
- BioStar® OIA® FLU and BioStar® OIA® FLU A/B; rapid influenza diagnostic tests which were commercialised and subsequently marketed by Inverness Medical as part of their BioStar product range.
Please note: Biota is not the manufacturer or marketer of these products. Enquiries about the products should be directed to GlaxoSmithKline in the case of Relenza, or to Inverness Medical in the case of the OIA FLU range.